Parkinson’s disease “end-of-dose phenomenon” refers to the phenomenon that patients with Parkinson’s disease have rhythmic fluctuations of symptoms after taking levodopa drugs. Many patients begin to experience such fluctuations in symptoms 1-3 years after taking the drug, and they gradually worsen, and the effective time of the drug gradually decreases, or even only 1-2 hours of efficacy per dose. Solutions include: increasing the dose of levodopa; maintaining the original dose while increasing the number of doses; switching to a restorative controlled-release agent; or adding a dopamine agonist, a B-type monoamine oxidase inhibitor, or a catechol-oxygen-site methyltransferase inhibitor. The “switch phenomenon” is a phenomenon in which a patient with Parkinson’s disease suddenly experiences an increase in symptoms, generalized rigidity, and difficulty walking, but the symptoms suddenly disappear after a few minutes without any treatment. The “switch” can occur at any time and in any state of the patient’s life, regardless of the time or dose of the drug. It may be caused by a dysfunction of dopamine receptors. “Morning stiffness” refers to a period of time after waking up every morning when patients with Parkinson’s disease have very heavy symptoms, stiffness, and difficulty moving around, but some patients will relieve themselves after a few minutes to half an hour, while some patients need levodopa drugs to relieve themselves. When levodopa drugs are first applied to treat Parkinson’s disease, if the dosage and usage are reasonable and the dosage is regular, and the concentration of levodopa is maintained at a relatively stable level, the occurrence of isokinetic disorder, switching phenomenon and morning stiffness can be postponed or even avoided. If the above-mentioned symptoms have already appeared and cannot be relieved by adjusting the medication, the most effective treatment modality at present – brain pacemaker surgery – can be considered. The electrical impulses from the implanted electrodes stimulate the relevant nuclei in the brain to suppress abnormal nerve signals, thereby improving the symptoms of Parkinson’s disease, such as tremor, rigidity, motor retardation and unsteadiness, and reducing the “end-of-dose phenomenon”, “switch phenomenon” and “morning stiffness” caused by taking medication, It also reduces the “end-of-dose phenomenon”, “switch phenomenon”, and “morning stiffness” produced by taking the drug, and significantly improves the quality of life.